Literature DB >> 25002353

[Secondary chondrosarcoma: radiopathological correlation].

G A Lozano Martínez1, J Llauger Rosselló2.   

Abstract

Chondrosarcomas are malignant bone tumors originating in cartilage. Chondrosarcoma is the third most common malignant bone tumor after multiple myeloma and osteosarcoma. About 75% of chondrosarcomas are primary lesions. The remaining 25% belong to special categories such as histologic variants and secondary forms. A secondary chondrosarcoma is one that appears in a pre-existing benign chondral lesion; the different types of secondary chondrosarcomas include solitary osteochondroma, multiple osteochondromatosis, enchondroma, the different types of enchondromatosis, and primary synovial chondromatosis. The incidence of this malignant transformation varies widely in function of the type of lesion. In this article, we discuss and illustrate the different types of secondary chondrosarcomas, placing special emphasis on the imaging findings that should alert to these lesions and give radiologists a key role in the diagnosis, management, and follow-up of these patients.
Copyright © 2013 SERAM. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Chondromatosis; Chondrosarcoma; Condroma; Condromatosis; Condrosarcoma; Enchondroma; Magnetic resonance imaging; Multidetector computed tomography; Osteochondroma; Osteocondroma; Resonancia magnética; Tomografía computarizada multidetector

Mesh:

Year:  2014        PMID: 25002353     DOI: 10.1016/j.rx.2014.04.004

Source DB:  PubMed          Journal:  Radiologia        ISSN: 0033-8338


  2 in total

1.  Long non-coding RNA BCAR4 promotes chondrosarcoma cell proliferation and migration through activation of mTOR signaling pathway.

Authors:  Xiaolong Shui; Chengwei Zhou; Wei Lin; Yang Yu; Yongzeng Feng; Jianzhong Kong
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-11

2.  DDX10 and BYSL as the potential targets of chondrosarcoma and glioma.

Authors:  Xuemin Quan; Changsong Zhao; Zhengrong Gao; Yao Zhang; Rugang Zhao; Jingjing Wang; Qiang Zhang
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.